CovidVax show full list

mRNA-1273 LNPencapsulated mRNA

Moderna + NIAID + Lonza + Catalent Inc. + BIOQUAL
vaccine type: RNA-based
Distribution updates
Oct 01Moderna CEO said that his company's coronavirus vaccine won't be ready for public distribution until spring next year (by
Human Testing updates (clinical trials)



started March 16 2020

with 155 healthy volunteers aged 18-99

trial location: USA

» clinical trial details



started May 25 2020

with 600 healthy volunteers aged 18+

trial location: USA

» clinical trial details



started July 27 2020

with 30000 healthy volunteers aged 18+

trial location: USA

» clinical trial details

Nov 16Moderna's vaccine meets its primary efficacy endpoint in the first interim analysis of the Phase 3 COVE study (by
Oct 22Moderna has completed the enrollment of 30000 participants for the Phase 3 COVE study of mRNA-1273 (by
Sep 29Moderna's Phase 1 trial of its vaccine has shown that it's well tolerated and generates a strong immune response in older adults (by
Sep 29Moderna announced the publication of a second interim analysis of Phase 1 study of mRNA-1273 (by
Aug 26Moderna presented new clinical data from the cohorts of older adults in the NIH-led Phase 1 study (by
Aug 26Phase 1 study of Moderna's vaccine efficacy showed promising results in older adults (by
Aug 20Moderna's Phase 3 study is to evaluate the efficacy,safety and immunogenicity of mRNA-1273 in adults aged 18+ (by
Jul 27Moderna announced today that the Phase 3 study of its vaccine has begun dosing participants (by
Jul 27Moderna's Phase 3 trial will be conducted at US clinical research sites enrolling 30000 adults (by
Jul 23Medidata will collaborate with Moderna to support clinical trials including Phase 3 trial (by
Jul 14Moderna announced the publication of an interim analysis of the Phase 1 study of its vaccine (by
Jul 08Moderna announced that it has completed enrollment for both cohorts of the Phase 2 study (by
Jun 11mRNA-1273 is currently in Phase 2 clinical trial moving towards Phase 3 efficacy evaluation (by
Jun 02Moderna's vaccine will enter Phase 3 trial in July by testing 30000 individuals in the US (by
May 29The first participants in Moderna's Phase 2 studies have been dosed with the vaccine today (by
May 18Neutralising antibodies were found in the first 8 people who took part in Moderna's safety trials (by
May 12FDA has granted Fast Track designation for Moderna's mRNA vaccine candidate (by
May 07Moderna will start clinical trials phase 2 shortly and expects to start phase 3 early in the summer (by
Apr 27Moderna is planning to test 600 individuals for phase 2 clinical trials starting in Q2 2020 (by
Apr 13On March 16 Moderna was the first research company in the world to start clinical trials (by
Mar 18Moderna starts phase 1 trials on 45 healthy adults to evaluate safety and immunogenicity (by
Animal Testing updates (pre-clinical trials)
start date: February 2020
Aug 28Vaccination of non-human primates with mRNA-1273 induced robust SARS-CoV-2 neutralizing activity (by
Aug 10BIOQUAL announced the publication of the successful testing of mRNA-1273 in non-human primates (by
Aug 05mRNA-1273 protected mice from coronavirus according to research published today in Nature (by
Aug 05mRNA-1273 is currently in Phase 3 efficacy evaluation and protects lungs and noses of mice (by
Jul 28Moderna published in The New England Journal of Medicine its preclinical study (by
Jul 28mRNA-1273 induced immunicity and controlled the coronavirus in the airways of rhesus macaques (by
Mar 16Moderna's vaccine has shown promise in animal models (by
early development updates
Nov 17Moderna announced today that the EMA has started a rolling review of mRNA-1273 (by
Nov 16Moderna announced new data showing that mRNA-1273 remains stable at 2°to 8°C the temperature of a standard fridge for 30 days (by
Nov 13Moderna announced today Swissmedic has started a rolling review of mRNA-1273 following positive analysis of the Phase 1 study (by
Oct 27Moderna announced that MHRA in the UK has started the rolling review process of mRNA-1273 (by
Oct 14Moderna received confirmation from EMA that its vaccine is eligible for submission of an application for a European Union Marketing Authorization (by
Oct 13Moderna today announced the initiation of a rolling submission to Health Canada for mRNA-1273 (by

Coalition for Epidemic Preparedness (CEPI) + US govt's BARDA
Aug 11US Govt awarded Moderna up to $1.525 billion for the manufacturing and delivery of 100m doses (by
Jul 26Moderna modified its contract with BARDA with additional $472M to support Phase 3 study (by
Jun 10BARDA is expanding its partnership with Moderna to increase the manufacturing capacity (by
Jun 03Trump Administration has selected Moderna's vaccine among top 5 most likely to be produced (by
Apr 16BARDA will boost Moderna's development of a vaccine by awarding up to $483 million (by
Jan 23Moderna announces funding from CEPI to accelerate development of mRNA vaccine (by
Jul 09Moderna and Rovi announced partnership for large scale manufacturing of Moderna's vaccine (by
Jun 25Moderna and Catalent announce collaboration for fill-finish manufacturing of Moderna's vaccine (by
May 01Moderna struck a deal with Swiss firm Lonza to manufacture up to 1B doses per year (by

contact | about | ©2020 project